Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Risk of Subsequent Skin Cancer Seen Among Organ Transplant Recipients
November 24th 2022The study's goal was to clarify possible second and third skin cancer development patterns among organ transplant recipients who developed more than 1 instance of skin cancer and to better characterize this patient population by patient age and transplanted organ type.
Read More
Dr Tochi Okwuosa: There Is a Great Need for Better CVD Risk Prediction in Cardio-Oncology
November 19th 2022In an interview at this year’s American Heart Association Scientific Sessions meeting in Chicago, Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, discussed the importance of addressing cardiovascular disease (CVD) prevention in patients with cancer who are undergoing treatment.
Read More
Disease Characteristics Vary Widely Among Patients With CRSwNP or CRSsNP
November 19th 2022The investigators of this new study wanted to more clearly define the patient characteristics of the 2 main types of chronic rhinosinusitis: with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP).
Read More
Dr Emeline Aviki: Telehealth Allows Patients a Quick Return to Daily Life
November 19th 2022There is a major role for telehealth in oncology care, not only for its convenience but also for giving clinicians the ability to scale nononcologic visits, explained Emeline Aviki, MD, MBA, FACOG, assistant attending gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and lead of the MSKCC Affordability Working Group.
Read More
Hypertension Knowledge, Training Lacking Within Internal Medicine Programs
November 17th 2022Despite the commonality of hypertension among US adults—nearly half of them have elevated blood pressure—hypertension education among internal residents has not kept up with the condition’s prevalence.
Read More
Sacubitril/Valsartan Linked to Improved Cardiac Autonomic Nervous System in HFrEF
November 15th 2022This international study, from investigators in Germany and Austria, looked at the effect sacubitril/valsartan can have among patients who have heart failure with reduced ejection fraction (HFrEF) and the impact on their cardiac autonomic nervous system.
Read More
Presence of CRS May Indicate Potential to Develop Ulcerative Colitis
November 14th 2022Despite knowledge of chronic rhinosinusitis and inflammatory bowel diseases (IBDs) sharing dysfunctional mucosa, little is known of potential associations between sinusitis and IBD, which prompted this new study.
Read More
Dr Stephen Schleicher: We Need to Focus More on Financial Toxicity
November 14th 2022Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, addresses the “huge problem” of financial toxicity among patients with cancer, which can be attributed in part to both the high price of targeted treatments and even from ordering only necessary testing.
Read More
Dr Neil Gross on Potential Impact of Future Novel Treatments for cSCC
November 12th 2022Currently, there is no treatment approved for resectable cutaneous squamous cell carcinoma (cSCC), nor do we have biomarkers to predict treatment response, noted Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center
Read More
Dr Amresh Raina Addresses Gender Differences in HF Presentation
November 12th 2022Disease symptomatology may be the same, but the presentation of heart failure (HF) and heart attacks differ between women and men, explained Amresh Raina, MD, of the Allegheny Health Network in Pittsburgh, Pennsylvania.
Read More
Comorbid Septic Shock, HFrEF Linked to Lack of Guideline-Recommended Treatment
November 10th 2022Patients with heart failure frequently suffer from fluid overload, and for those with heart failure with reduced ejection fraction (HFrEF) also suffering from septic shock—a condition often treated with fluids—more data are needed on outcomes following fluid administration.
Read More
Nasal Cytology Produces Comparable Results to Surgery in CRSwNP
November 9th 2022The investigators of a new study evaluated if nasal cytology was a reliable method to identify type 2 inflammation in patients who have chronic rhinosinusitis with nasal polyps (CRSwNP), which could then facilitate patient selection for biological drug utilization via endotypization.
Read More
Dr Tochi Okwuosa: We Need More Data on Cardio-Toxicity From Radiation
November 8th 2022Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, delivered several presentations at the American Heart Association’s Scientific Sessions this year. Chief among them were the importance of cardiovascular health in cancer survivors and cardio-toxicity from cancer treatments.
Read More
Dr Kausik Ray: ORION-3 Data Show Inclisiran Produces Durable Sustained LDL-C Reduction
November 7th 2022Kausik K. Ray, MB ChB, MD, MPhil, is professor of public health and a consultant cardiologist at Imperial College London in the United Kingdom. At this year’s American Heart Association’s Scientific Sessions, he presented findings from a 4-year open-label extension study of inclisiran, a small interfering RNA that targets proprotein convertase subtilisin kexin type 9 to lower low-density lipoprotein cholesterol (LDL-C).
Read More
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, professor of medicine and the Gerald S. Berenson Endowed Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the results of the recently halted FRESH trial, why there is such a great need for new antihypertensive agents, and possible contributory factors to outcome disparities between Black and White patients.
Read More
Dr Mikhail Kosiborod Discusses the Clinical Importance of the Latest DELIVER Data on Dapagliflozin
November 7th 2022The DELIVER trial is the largest trial to date of SGLT2 inhibitor use in heart failure, and these latest data on dapagliflozin in heart failure with mildly reduced or preserved ejection fraction show an extensive benefit on health status, noted Mikhail Kosiborod, MD, cardiologist at St. Luke's Mid America Heart Institute in Kansas City, Missouri.
Read More
Dr Stephen J. Greene: New VICTORIA Trial Data Show Benefit to Vericiguat In-Hospital Initiation
November 7th 2022The latest real-world clinical practice data from the VICTORIA trial of vericiguat bolster previous data on the medication’s benefit by showing that 92% of patients hospitalized for a worsening heart failure event would be eligible to start the therapy and that doing so would reduce their risk of heart failure hospitalization and cardiovascular death, noted Stephen J. Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.
Read More
Dr Michael Portman: Edoxaban Facilitates Easier Treatment, Improved QOL in Pediatric Cardiac Disease
November 6th 2022In the ENNOBLE-ATE trial, Michael A. Portman, MD, FAHA, director, Pediatric Cardiovascular Research, Center for Integrative Brain Research, and professor of pediatrics at Seattle Children's, and his team evaluated the safety and efficacy of edoxaban, a direct oral anticoagulant previously only used among adult patients, among pediatric patients with cardiac disease.
Read More
Dr Douglas Mann Discusses Novel CRISPR/Cas9 Findings in ATTR Amyloid Cardiomyopathy
November 6th 2022Douglas L. Mann, MD, professor of medicine at Washington University School of Medicine in St. Louis and editor-in-chief of JACC: Basic to Translational Science discussed the first set of data reported on NTLA-2001, a novel investigative intravenous agent that targets the TTR gene and TTR protein levels, which have been shown to play a role in development of cardiac transthyretin (ATTR) amyloidosis.
Read More
Macitentan Safety, Effectiveness in PAH Confirmed in New Analysis
November 3rd 2022Two data sets from patients with severe pulmonary arterial hypertension (PAH) show the benefits of macitentan (Opsumit) monotherapy despite guidelines calling for combination therapy, even among patients with World Health Organizational functional class I-II disease.
Read More
Dr Neil Gross Discusses the Implications of pCR on Additional Treatment in Skin Cancer
November 2nd 2022Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center, discusses the results of study he and his team conducted in the setting of resectable stage II to IV cutaneous squamous cell carcinoma.
Read More
Dr Amresh Raina Illuminates Top Concerns in Asymptomatic Heart Failure
November 1st 2022Risk factors not properly addressed in patients with asymptomatic heart failure, such as high blood pressure and having diabetes or mild heart valve problems, can lead to structural heart problems or heart failure itself, noted Amresh Raina, MD, of the Allegheny Health Network in Pittsburgh, Pennsylvania.
Read More